Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 6/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.46 |
| ▸ | CNR2 | P34972 | 13/20 | 0.37 |
| ▸ | CNR1 | P21554 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13500286 | 0.93 | SLC1A3 (0.49) | SLC1A3SLC1A2SLC1A1CNR2CNR1 | |
| SCHEMBL13499741 | 0.84 | SLC1A3 (0.45) | SLC1A3SLC1A2SLC1A1CNR2CNR1 | |
| SCHEMBL13463178 | 0.83 | SLC1A3 (0.44) | SLC1A3SLC1A2SLC1A1CNR2 | |
| SCHEMBL13435111 | 0.81 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1CNR2CNR1 | |
| SCHEMBL13499749 | 0.79 | SLC1A3 (0.49) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13501749 | 0.77 | CNR2 (0.39) | SLC1A3SLC1A2SLC1A1CNR2CNR1 | |
| SCHEMBL13461547 | 0.77 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13435119 | 0.76 | SLC1A3 (0.45) | SLC1A3SLC1A2SLC1A1CNR2 | |
| SCHEMBL13500237 | 0.75 | SLC1A3 (0.39) | SLC1A3SLC1A2SLC1A1CNR2CNR1 | |
| SCHEMBL13500175 | 0.75 | LMNA (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655647-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20100009966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090170831-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | SLC1A3 801/4885SLC1A2 537/4885SLC1A1 743/4885 |
| US-20090170831-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | SLC1A3 864/4885SLC1A2 667/4885SLC1A1 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.